Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to CD3ζ signaling domains. And the vector product was designed for the treatment of NSCLC.
|
CAR Construction :
Fig.1 Antitumor capabilities of EGFR antibodies in EGFRvIII and wtEGFR-expressing gliomasphere lines. Representative plots for the in vitro inhibition of proliferation in gliomaspheres expressing EGFRvIII after 7 days of treatment with 10 µg/mL of singular antibodies or domain III-targeting antibodies in combination with ch806 measured by Vialight assay Jin, K. T., Chen, B., Liu, Y. Y., Lan, H., & Yan, J. P. (2021). Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell International, 21(1), 1-15. |
|
CAR Construction :
Fig.2 EGFR expression on different human tumor cell lines. Analysis of cell surface EGFR expression level was performed by flow cytometry. Albert, S., Arndt, C., Koristka, S., Berndt, N., Bergmann, R., Feldmann, A., ... & Bachmann, M. (2018). From mono-to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget, 9(39), 25597. |
|
CAR Construction :
Fig.3 Comparison of the affinities of the mono- and bivalent EGFR-specific TMs. For estimation of the respective Kd value increasing amounts of monovalent α-EGFR TM (triangle) or bivalent α-EGFR-EGFR TM (rectangle). Albert, S., Arndt, C., Koristka, S., Berndt, N., Bergmann, R., Feldmann, A., ... & Bachmann, M. (2018). From mono-to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget, 9(39), 25597. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGFR (Necitumumab) h(CD3ζ) CAR, pCDCAR1 (CAR-YF677). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
